Free Trial
NYSE:ENZ

Enzo Biochem (ENZ) Stock Price, News & Analysis

Enzo Biochem logo
$0.43 +0.00 (+1.06%)
Closing price 03/28/2025 03:59 PM Eastern
Extended Trading
$0.34 -0.10 (-22.27%)
As of 03/28/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Enzo Biochem Stock (NYSE:ENZ)

Key Stats

Today's Range
$0.41
$0.45
50-Day Range
$0.42
$0.67
52-Week Range
$0.41
$1.30
Volume
134,136 shs
Average Volume
119,640 shs
Market Capitalization
$22.59 million
P/E Ratio
N/A
Dividend Yield
92.81%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Enzo Biochem, Inc. develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. It also provides AMPIVIEW in situ hybridization probes for enhanced detection of low expressed targets useful in the growing spatial biology space; reagents and assays for cell and gene therapy research and development; POLYVIEW PLUS Enhanced Immunohistochemistry platform, offers solutions within the area of anatomical pathology through optimized assays; Enhanced Immunoassays, pushing sensitivity to expand immunoassay applications for basic research, bioprocess, and diagnostics; AMPIPROBE, a nucleic acid amplification platform; and Axxora.com, a proven distribution platform for original manufacturers of innovative research reagents. The company's proprietary products and technologies in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. It markets its products and services through its direct sales force and a network of distributors. The company was incorporated in 1976 and is headquartered in Farmingdale, New York.

Remove Ads

Enzo Biochem Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
11th Percentile Overall Score

ENZ MarketRank™: 

Enzo Biochem scored higher than 11% of companies evaluated by MarketBeat, and ranked 912th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Enzo Biochem.

  • Percentage of Shares Shorted

    0.83% of the float of Enzo Biochem has been sold short.
  • Short Interest Ratio / Days to Cover

    Enzo Biochem has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enzo Biochem has recently increased by 14.84%, indicating that investor sentiment is decreasing significantly.
  • Dividend Leadership

    Enzo Biochem is a leading dividend payer. It pays a dividend yield of 85.11%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    Enzo Biochem does not have a long track record of dividend growth.

  • Read more about Enzo Biochem's dividend.
  • Percentage of Shares Shorted

    0.83% of the float of Enzo Biochem has been sold short.
  • Short Interest Ratio / Days to Cover

    Enzo Biochem has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Enzo Biochem has recently increased by 14.84%, indicating that investor sentiment is decreasing significantly.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Enzo Biochem this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Enzo Biochem insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.40% of the stock of Enzo Biochem is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 36.90% of the stock of Enzo Biochem is held by institutions.

  • Read more about Enzo Biochem's insider trading history.
Receive ENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enzo Biochem and its competitors with MarketBeat's FREE daily newsletter.

ENZ Stock News Headlines

Enzo Biochem to delist stock from NYSE
Alert: DOGE goes live
Elon will most likely be at the helm of it all. And just days from now, could bring about the biggest economic transformation in American history. See, there's one particular part of Elon and Trump's plans that you need to pay special attention to right now.
Enzo Biochem reports Q2 revenue $7.3M vs. $6.2M in Q1
See More Headlines

ENZ Stock Analysis - Frequently Asked Questions

Enzo Biochem's stock was trading at $0.7143 at the start of the year. Since then, ENZ shares have decreased by 39.7% and is now trading at $0.4310.
View the best growth stocks for 2025 here
.

Enzo Biochem, Inc. (NYSE:ENZ) announced its quarterly earnings results on Monday, March, 17th. The medical research company reported ($0.02) earnings per share for the quarter. The medical research company had revenue of $7.33 million for the quarter. Enzo Biochem had a negative net margin of 75.34% and a negative trailing twelve-month return on equity of 7.96%.

Top institutional shareholders of Enzo Biochem include Renaissance Technologies LLC (4.53%), Mink Brook Asset Management LLC (1.55%), Wittenberg Investment Management Inc. (0.36%) and Lepercq Multi Asset Fund (0.24%). Insiders that own company stock include James G Wolf, Hamid Erfanian, David Bench and Kara Cannon.
View institutional ownership trends
.

Shares of ENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Enzo Biochem investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and OneLife Technologies (OLMM).

Company Calendar

Last Earnings
3/17/2025
Today
3/28/2025
Next Earnings (Estimated)
6/11/2025
Fiscal Year End
7/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NYSE:ENZ
Employees
520
Year Founded
1976

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-26,080,000.00
Pretax Margin
-23.79%

Debt

Sales & Book Value

Annual Sales
$29.09 million
Price / Cash Flow
N/A
Book Value
$1.09 per share
Price / Book
0.40

Miscellaneous

Free Float
46,288,000
Market Cap
$22.59 million
Optionable
Optionable
Beta
0.80

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NYSE:ENZ) was last updated on 3/29/2025 by MarketBeat.com Staff
From Our Partners